No Data
Another wave! The revised version of the "Biosecurity Act" introduced to the legislative agenda in the US Senate, but the suspense of "breaking through" still lingers.
①On the 23rd local time in the United States, the U.S. Senate will include Amendment S.3558 in the Senate legislative agenda by general order, confirming the new name of the bill, and there is unusual movement in the BrightGene system; ②Amendment S.3558 does not include the "grandfather clause" of the House version of the Biosecurity Act regarding exemptions, nor does it make any changes to the entities involved.
BeiGene Initiated at Outperform at JMP Securities on Strength of Brukinsa
JMP Securities Initiates Coverage On BeiGene With Market Outperform Rating, Announces Price Target of $288
Beigene's stock price was hit by bearish news! It is accused of stealing trade secrets. The company denies the accusations and vows to vigorously defend itself.
①AbbVie has once again filed a lawsuit against Beigene, accusing Beigene of stealing core business secrets to develop BTK degraders. ②Previously, AbbVie sued Beigene for patent infringement of zanubrutinib (BTK inhibitor), and the case is under review. Beigene stated that this has not had a negative impact on the research and sales of zanubrutinib in the United States.
Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
Another unreasonable suppression! The U.S. House of Representatives has passed the Biosecurity Act, and wuxi apptec and wuxi bio have quickly responded.
①The U.S. House of Representatives passed the draft of the Biosecurity Act (H.R.8333) with 306 votes in favor and 81 votes against. ②Wuxi Apptec, Wuxi Bio, and other companies strongly opposed it. ③This bill still needs to be voted on by the Senate and the versions passed by both houses need to be reconciled before it can be submitted to the U.S. President for signing into law.